Halloween 2025 blends ancient traditions with modern media, tourism, and community celebrations, showcasing the holiday's enduring appeal.
Novo Nordisk launches a rival $56.50 bid to acquire U.S. obesity biotech Metsera, challenging Pfizer's existing agreement and sparking a bidding war over Metsera's promising GLP-1 pipeline.
Halloween 2025 blends ancient traditions with modern media, tourism, and community celebrations, showcasing the holiday's enduring appeal.
Novo Nordisk launches a rival $56.50 bid to acquire U.S. obesity biotech Metsera, challenging Pfizer's existing agreement and sparking a bidding war over Metsera's promising GLP-1 pipeline.